A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r (Q43708339)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r |
scientific article |
Statements
1 reference
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r (English)
1 reference
Jürgen K Rockstroh
1 reference
Jean-Michel Molina
1 reference
Joseph Gathe
1 reference
Marshall W Fordyce
1 reference
Javier Szwarcberg
1 reference
GS-236-0103 Study Team
1 reference
Edwin DeJesus
1 reference
Keith Henry
1 reference
Srinivasan Ramanathan
1 reference
Xuelian Wei
1 reference
Andrew Plummer
1 reference
Michael Abram
1 reference
Andrew K Cheng
1 reference
1 April 2013
1 reference
1 reference
Identifiers
1 reference